Patient characteristics
| . | No. patients (%) . | |
|---|---|---|
| No. patients | 85 | |
| Age, median (y) | 62 | |
| Sex | ||
| Male | 66 (77.6) | |
| Female | 19 (22.4) | |
| Tumor stage | ||
| III | 21 (24.7) | |
| IV | 47 (55.3) | |
| Recurrent | 17 (20.0) | |
| Histopathology | ||
| Adenocarcinoma | 47 (55.3) | |
| Squamous cell carcinoma | 22 (25.9) | |
| Large cell carcinoma | 3 (3.5) | |
| Others | 13 (15.3) | |
| Performance status | ||
| 0 | 6 (7.0) | |
| 1 | 72 (84.7) | |
| 2 | 7 (8.3) | |
| Maximal SUV | ||
| ≤7.5 | 44 (51.8) | |
| >7.5 | 41 (48.2) | |
| Location of maximal SUV | ||
| Primary tumor | 69 (81.2) | |
| Locoregional lymph node | 11 (12.9) | |
| Distant metastasis | 5 (5.9) | |
| Tumor response to first-line chemotherapy | ||
| Partial response | 40 (47.1) | |
| Stable disease | 29 (34.1) | |
| Progressive disease | 16 (18.8) | |
| . | No. patients (%) . | |
|---|---|---|
| No. patients | 85 | |
| Age, median (y) | 62 | |
| Sex | ||
| Male | 66 (77.6) | |
| Female | 19 (22.4) | |
| Tumor stage | ||
| III | 21 (24.7) | |
| IV | 47 (55.3) | |
| Recurrent | 17 (20.0) | |
| Histopathology | ||
| Adenocarcinoma | 47 (55.3) | |
| Squamous cell carcinoma | 22 (25.9) | |
| Large cell carcinoma | 3 (3.5) | |
| Others | 13 (15.3) | |
| Performance status | ||
| 0 | 6 (7.0) | |
| 1 | 72 (84.7) | |
| 2 | 7 (8.3) | |
| Maximal SUV | ||
| ≤7.5 | 44 (51.8) | |
| >7.5 | 41 (48.2) | |
| Location of maximal SUV | ||
| Primary tumor | 69 (81.2) | |
| Locoregional lymph node | 11 (12.9) | |
| Distant metastasis | 5 (5.9) | |
| Tumor response to first-line chemotherapy | ||
| Partial response | 40 (47.1) | |
| Stable disease | 29 (34.1) | |
| Progressive disease | 16 (18.8) | |